#United States #Boston #CFO Appointment #Bambusa Therapeutics #Jonathan Lieber

Bambusa Therapeutics Welcomes Jonathan I. Lieber as Chief Financial Officer

In a strategic move aimed at amplifying its trajectory of growth, Bambusa Therapeutics, Inc. announced the appointment of Jonathan I. Lieber, M.B.A., as their new Chief Financial Officer (CFO). The clinical-stage biotechnology company specializes in developing next-generation bispecific antibodies, focusing on immunology and inflammation—a vital area in today’s healthcare landscape. This appointment marks a pivotal moment for Bambusa as it seeks to bolster its financial framework and accelerate its innovative pipeline.

Jonathan Lieber enters Bambusa with over three decades of leadership experience in financial, strategic, and operational roles within the biotechnology sector. His extensive background equips him with unique insights into navigating the complex world of clinical development and financing. “We are thrilled to welcome Jon to Bambusa at a crucial stage in our evolution,” expressed Bambusa’s Founder and CEO, Shanshan Xu, M.D., Ph.D. “His vast experience in guiding biotech companies through significant phases of growth, combined with his collaborative leadership style, positions him as an exceptional asset to our team.”

Prior to joining Bambusa, Mr. Lieber served as the CFO of Rallybio Corporation, a publicly traded company where he notably influenced financial strategies and operations since February 2023. Before his role at Rallybio, he held pivotal positions at Applied Genetic Technologies Corporation (AGTC), Histogenics Corporation, and several others, where he honed his skills in financial leadership and strategic operational guidance. His career began in investment banking at renowned firms like Salomon Brothers and Cowen and Company, providing him with a robust foundation in financial markets and investment strategies.

“Bambusa’s unique combination of innovative science, a robust and diversified portfolio, and a team with a proven track record strongly attracted me,” Mr. Lieber remarked on his motivation to join the company. “Our collective experience in drug development, strategic partnerships, and company building will be essential in transforming promising scientific research into concrete clinical results.” His eagerness to collaborate with Shanshan Xu and the dedicated team at Bambusa underlines his commitment to fostering organizational capabilities that align with Bambusa’s vision of emerging as a leading player in immunology therapies.

Bambusa Therapeutics is not just promising with its leadership; the company focuses on developing groundbreaking drug molecules such as BBT001, a bispecific antibody with first-in-class potential aimed at treating conditions like atopic dermatitis. Another key project, BBT002, targets Type 2 inflammatory disorders, indicating the breadth of Bambusa’s innovative approaches to chronic diseases—demonstrating high ambition in the competitive biotech arena.

Furthermore, Mr. Lieber is not only bringing financial expertise to Bambusa; he also holds significant board experience, serving on the boards of various organizations, including Decoy Therapeutics, Inc. and Mindwalk Holdings Corp. His comprehensive knowledge in drug development and company financial operations is poised to empower Bambusa in achieving its long-term goals.

In conclusion, Jonathan I. Lieber’s appointment as CFO not only strengthens Bambusa’s leadership team but positions the company strategically for the future. As they continue to advance their pipeline of next-generation therapies, their commitment to delivering transformative medicines remains steadfast—a commitment echoed by both leadership and the teams dedicated to this goal. Through Lieber’s guidance, Bambusa anticipates a refined approach to financial stability that will enhance their ability to innovate and elevate patient care across various stages of life.

For more information about their projects and vision, visit Bambusa Therapeutics.

• ---

Media and Investor Contact
Email: [email protected]
Source: Bambusa Therapeutics
Updated: October 7, 2026